Analysts Set Pacira BioSciences, Inc. (NASDAQ:PCRX) Price Target at $23.50

Pacira BioSciences, Inc. (NASDAQ:PCRX) has received a consensus recommendation of “Hold” from the ten analysts that are presently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, four have issued a hold rating and four have assigned a buy rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $23.50.

Several equities research analysts recently weighed in on the stock. Truist Financial downgraded shares of Pacira BioSciences from a “buy” rating to a “sell” rating and reduced their price target for the company from $30.00 to $8.00 in a research report on Tuesday, August 13th. StockNews.com downgraded shares of Pacira BioSciences from a “strong-buy” rating to a “buy” rating in a research report on Monday, August 12th. JPMorgan Chase & Co. reissued an “underweight” rating and issued a $10.00 price target (down from $45.00) on shares of Pacira BioSciences in a report on Monday, August 12th. Piper Sandler cut shares of Pacira BioSciences from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $42.00 to $11.00 in a research note on Monday, August 12th. Finally, HC Wainwright lowered their target price on Pacira BioSciences from $57.00 to $39.00 and set a “buy” rating for the company in a research report on Monday, August 12th.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC increased its position in shares of Pacira BioSciences by 229.6% during the second quarter. GAMMA Investing LLC now owns 1,338 shares of the company’s stock worth $38,000 after acquiring an additional 932 shares during the period. Park Place Capital Corp purchased a new position in shares of Pacira BioSciences in the 2nd quarter valued at approximately $46,000. Innealta Capital LLC purchased a new position in shares of Pacira BioSciences in the second quarter worth $50,000. nVerses Capital LLC raised its stake in Pacira BioSciences by 800.0% in the 2nd quarter. nVerses Capital LLC now owns 1,800 shares of the company’s stock worth $51,000 after acquiring an additional 1,600 shares during the last quarter. Finally, Quest Partners LLC acquired a new stake in shares of Pacira BioSciences during the second quarter worth about $113,000. Hedge funds and other institutional investors own 99.73% of the company’s stock.

Pacira BioSciences Trading Up 5.3 %

PCRX opened at $17.81 on Friday. Pacira BioSciences has a 52 week low of $11.16 and a 52 week high of $35.95. The stock has a market cap of $822.29 million, a PE ratio of -8.77 and a beta of 0.82. The company has a quick ratio of 1.89, a current ratio of 2.25 and a debt-to-equity ratio of 0.51. The business has a 50 day moving average of $16.53 and a 200-day moving average of $19.67.

About Pacira BioSciences

Pacira BioSciences, Inc engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension; and iovera system, a non-opioid handheld cryoanalgesia device used to produce controlled doses of cold temperature to targeted nerves.